Dr. Jack Rubin MD

Medical Director and Chief Executive Officer , Los Angeles Vascular Center

GLG News by Dr. Jack Rubin MD, Medical Director and Chief Executive Officer

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Tekturan losers blood pressure and proteinuria simultaneously

May 27, 2008

Analysis of:New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone | www.novartis.com

While no more would argue that control of systolic hypertension is crucial to preventing the consequences of hypertension such as congestive heart failure, MI's, left ventricular hyperthrophy, stroke and kidney failure there are other factors that are associated with these disease states. One of these is proteinuria.

sitaglitpin

November 6, 2006

Analysis of:MEDICARE ADDS PERFORMANCE-BASED PAYMENTS FOR PHYSICIANS | www.cms.hhs.gov

This drug is from a new class of agents that treat type II diabetes. The advantages of this class of drugs is that there is no hypoglycemia nor is there weight gain on those patients being treated with them.

Benefits of Novartis Combination Drug Regimen

June 16, 2006

Analysis of:Novartis Reports Two Heart Drugs Are Safe, Effective | online.wsj.com

Novartis is introducing a combination of valosartan and amlodipine to treat hypertension in the marketplace. This is a good combination because those patients who cannot tolerate ACE-I due to cough or, more rarely, angioneurotic edema, can now use this new agent to treat hypertension instead of Lotrel, which has as combination of an ACE-I and amlodipine.

Valosartan offers not only renal and cardiac protection, an effect seen independent of blood pressure control, it also reduces the pedal edema seen in many patients using amlodipine.

Other benefits are having a combination drug giving 2 different acting agents for one copayment price.

Reduciton of neovascularization using Rosigiltazone

June 16, 2006

Analysis of:Rosiglitazone may delay progression of severe diabetic retinopathy | www.ophthalmologytimes.com

Diabetics had fewer instances of neovascularization of their retinas while using Rosiglitazone.

This could lower the morbidity of diabetic retinopathy in diabetic patients as well as lowering health care cost for diabetic retinopathy in these patients.

Use of Zerenex in ESRD as a phosphate binder

June 7, 2006

Analysis of:Zerenex in Phase II Clinical Development for Treatment of Hyperphosphatemia in ESRD Patients | www.eneph.com

Zerenex is a phosphate binder that contains iron.

This could be a new phosphate binder without danger of lanthanam build up as could be seen with Fosrenol.

CRP levels with Valsartan Treatment

June 6, 2006

Analysis of:: Valsartan, Blood Pressure Reduction, and C. reactive protein. Primary Report of the Val-MARC Trial | hyper.ahajournals.org

The level of CRP fell in patients after being treated with Valsartan. This was not due to any significant blood pressure reduction in these patients, the blood pressure fell <2%. This study shows that Valsartan reduced CRP levels signifcantly and this was independent of any blood pressure reduction.

Page : 11 to 6 of 6

Subscribe to Updates

By RSS